feed,title,long_url,short_url
Benzinga,"Bristol Myers-JNJ Partnered Secondary Stroke Drug Misses Endpoint, But Companies See Enough Potential For Phase 3 Trials",https://benzinga.com/general/biotech/22/08/28663949/bristol-myers-jnj-partnered-secondary-stroke-drug-misses-endpoint-but-companies-see-enough-potent,https://bit.ly/3QR9LPj
